{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T06:03:58Z","timestamp":1789884238894,"version":"4.0.1"},"reference-count":36,"publisher":"Akademiai Kiado Zrt.","issue":"38","content-domain":{"domain":["www.akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2026,9,20]]},"abstract":"<jats:p>\n                    <jats:italic>Bevezet\u00e9s:<\/jats:italic>\n                    A sarcopeni\u00e1s elh\u00edz\u00e1s szorosan \u00f6sszef\u00fcgg a\n                    metabolikus diszfunkci\u00f3val t\u00e1rsult steatoticus m\u00e1jbetegs\u00e9g (MASLD)\n                    el\u0151fordul\u00e1s\u00e1val, de azok a t\u00e9nyez\u0151k, amelyek befoly\u00e1solj\u00e1k az \u00e9trend-kieg\u00e9sz\u00edt\u00e9s\n                    hat\u00e9konys\u00e1g\u00e1t az izomt\u00f6meg n\u00f6vel\u00e9s sor\u00e1n, eddig nem tiszt\u00e1zottak.\n                    <jats:italic>C\u00e9lkit\u0171z\u00e9s:<\/jats:italic>\n                    Munk\u00e1nkban azt vizsg\u00e1ltuk, hogy a\n                    cukorbetegs\u00e9g-specifikus, b\u00e9ta-hidroxi-b\u00e9ta-metil-butir\u00e1tot (HMB) tartalmaz\u00f3\n                    \u00e9trend-kieg\u00e9sz\u00edt\u0151 6 h\u00f3napig tart\u00f3 ad\u00e1sa milyen hat\u00e1ssal van a\n                    teljestest-denzitometri\u00e1val m\u00e9rt izomt\u00f6megre 2-es t\u00edpus\u00fa cukorbetegs\u00e9ggel\n                    kezelt, sarcopeni\u00e1s, elh\u00edzott \u00e9s egyidej\u0171leg a MASLD krit\u00e9riumainak megfelel\u0151\n                    betegekben; ezt k\u00f6vet\u0151en kerest\u00fck az izomt\u00f6meg-v\u00e1ltoz\u00e1s m\u00e9rt\u00e9ke \u00e9s az \u00e9letkor, a\n                    v\u00e9gtagi izomt\u00f6megindex, az egyes metabolikus param\u00e9terek, \u00edgy a hemoglobin-A1c-,\n                    a C-peptid- \u00e9s a trigliceridszint k\u00f6z\u00f6tti line\u00e1ris kapcsolatokat. Tov\u00e1bbi c\u00e9lunk\n                    e param\u00e9terek predikt\u00edv \u00e9rt\u00e9k\u00e9nek meghat\u00e1roz\u00e1sa volt a t\u00e1pl\u00e1l\u00e9kkieg\u00e9sz\u00edt\u00e9s\n                    hat\u00e9konys\u00e1g\u00e1nak el\u0151rejelz\u00e9s\u00e9ben.\n                    <jats:italic>M\u00f3dszer:<\/jats:italic>\n                    Keresztmetszeti\n                    vizsg\u00e1latunkba 2-es t\u00edpus\u00fa diabeteses 48 beteget vontunk be (55\u201384 \u00e9ves betegek,\n                    k\u00f6z\u00fcl\u00fck 40 n\u0151, 8 f\u00e9rfi, \u00e1tlag\u00e9letkoruk 72,48 \u00b1 8,26 \u00e9v). Kontrollcsoportk\u00e9nt 20\n                    hasonl\u00f3 kor\u00fa, komoly t\u00e1rsbetegs\u00e9gt\u0151l mentes szem\u00e9lyt v\u00e1lasztottunk, akiknek nem\n                    volt sem diabetes\u00fck, sem MASLD-juk. A steatosist tranziens elasztogr\u00e1fi\u00e1val\n                    igazoltuk. Miut\u00e1n az izomt\u00f6meg-v\u00e1ltoz\u00e1s m\u00e9rt\u00e9ke \u00e9s a t\u00f6bbi vizsg\u00e1lt param\u00e9ter\n                    k\u00f6z\u00f6tti kapcsolatot egyszer\u0171 line\u00e1ris regresszi\u00f3val azonos\u00edtottuk, logisztikus\n                    regresszi\u00f3s vizsg\u00e1lattal elemezt\u00fck az egyes param\u00e9terek predikt\u00edv \u00e9rt\u00e9k\u00e9t az\n                    izomt\u00f6meg-n\u00f6veked\u00e9s m\u00e9rt\u00e9k\u00e9re vonatkoz\u00f3an.\n                    <jats:italic>Eredm\u00e9nyek:<\/jats:italic>\n                    A\n                    betegek param\u00e9tereinek kezel\u00e9s el\u0151tti \u00e1tlag\u00e9rt\u00e9kei: testt\u00f6megindex: 27,80 \u00b1\n                    4,63, hemoglobin-A1c: 6,27 \u00b1 0,73, a steatosis m\u00e9rt\u00e9ke: 289 \u00b1 42 db\/m, v\u00e9gtagi\n                    izomt\u00f6megindex: 6213 \u00b1 786 g\/m\n                    <jats:sup>2<\/jats:sup>\n                    , android zs\u00edr ar\u00e1nya: 47,59 \u00b1 9,80%,\n                    teljes zs\u00edr ar\u00e1nya: 41,82 \u00b1 9,31%. A 6 h\u00f3napig tart\u00f3 kezel\u00e9st k\u00f6vet\u0151en 28\n                    betegn\u00e9l izomt\u00f6meg-n\u00f6veked\u00e9st figyelt\u00fcnk meg, k\u00f6z\u00fcl\u00fck 16 betegn\u00e9l a n\u00f6veked\u00e9s az\n                    eredeti izomt\u00f6meg 5%-\u00e1ig terjedt ki, 8 betegn\u00e9l 5% feletti volt, 4 betegn\u00e9l\n                    pedig az eredeti t\u00f6meg 10%-a feletti. 20 betegn\u00e9l enyhe izomt\u00f6meg-cs\u00f6kken\u00e9st\n                    \u00e9szlelt\u00fcnk, valamennyi\u00fck eset\u00e9ben ez a cs\u00f6kken\u00e9s az eredeti izomt\u00f6meg 5%-\u00e1ig\n                    terjedt ki. Az izomt\u00f6meg n\u00f6veked\u00e9s\u00e9nek m\u00e9rt\u00e9ke \u00e9s a t\u00f6bbi kiindul\u00e1si param\u00e9ter\n                    k\u00f6z\u00f6tt szignifik\u00e1ns m\u00e9rt\u00e9k\u0171 pozit\u00edv line\u00e1ris kapcsolatot tal\u00e1ltunk a C-peptid (r\n                    = 0,42, p = 0,03), az alkalikus foszfat\u00e1z (r = 0,51, p = 0,01) \u00e9s negat\u00edv\n                    kapcsolatot az \u00e9letkor (r = \u20130,39, p = 0,05) \u00e9s a trigliceridek (r = \u20130,41, p =\n                    0,04) eset\u00e9ben. A test\u00f6sszet\u00e9tel param\u00e9tereinek egyik\u00e9n\u00e9l sem tal\u00e1ltunk\n                    szignifik\u00e1ns kapcsolatot. Az izomt\u00f6meg v\u00e1ltoz\u00e1s\u00e1nak prediktorai a logisztikus\n                    regresszi\u00f3s anal\u00edzis alapj\u00e1n a k\u00f6vetkez\u0151k voltak: az \u00e9letkor negat\u00edv\n                    prediktork\u00e9nt (OR = 0,87, CI: 0,77\u20130,99, p = 0,04), a trigliceridszint a\n                    statisztikai szignifikancia hat\u00e1r\u00e1n negat\u00edv prediktork\u00e9nt (OR = 0,21, CI:\n                    0,04\u20131,03, p = 0,05) jelent meg.\n                    <jats:italic>K\u00f6vetkeztet\u00e9s:<\/jats:italic>\n                    A HMB-tartalm\u00fa\n                    \u00e9trend-kieg\u00e9sz\u00edt\u00e9s a betegek jelent\u0151s r\u00e9sz\u00e9n\u00e9l az izomt\u00f6meg n\u00f6veked\u00e9s\u00e9hez vagy\n                    annak meg\u0151rz\u00e9s\u00e9hez vezetett, az izomt\u00f6megben tapasztalt v\u00e1ltoz\u00e1sok azonban nem\n                    \u00e9rt\u00e9k el a statisztikai szignifikancia szintj\u00e9t, mik\u00f6zben az intervenci\u00f3ra adott\n                    v\u00e1lasz egy\u00e9ni volt, \u00e9s azt negat\u00edvan befoly\u00e1solta a magasabb \u00e9letkor \u00e9s a\n                    magasabb trigliceridszint. \u00cdgy e tekintetben a vizsg\u00e1lat negat\u00edv eredm\u00e9ny\u0171nek\n                    tarthat\u00f3. Ezen eredm\u00e9nyek \u00e9rtelmez\u00e9s\u00e9t korl\u00e1tozza az alacsony betegsz\u00e1m \u00e9s a\n                    vizsg\u00e1lat keresztmetszeti jellege, ez\u00e9rt azok meger\u0151s\u00edt\u00e9s\u00e9re nagyobb prospekt\u00edv\n                    vizsg\u00e1latok sz\u00fcks\u00e9gesek. Orv Hetil. 2026; 167(38): 1507\u20131515.\n                  <\/jats:p>","DOI":"10.1556\/650.2026.33671","type":"journal-article","created":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T05:54:55Z","timestamp":1789883695000},"page":"1507-1515","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":0,"title":["B\u00e9ta-hidroxi-b\u00e9ta-metilbutir\u00e1t tartalm\u00fa t\u00e1pl\u00e1l\u00e9kkieg\u00e9sz\u00edt\u0151 hat\u00e1sa az izomt\u00f6meg-param\u00e9terekre elh\u00edzott, anyagcserezavarral t\u00e1rsult steatoticus m\u00e1jbetegs\u00e9gben szenved\u0151 cukorbetegekben"],"prefix":"10.1556","volume":"167","author":[{"given":"Emil","family":"Fraenkel","sequence":"first","affiliation":[{"name":"I. Intern\u00e1 Klinika UNLP a LF UPJ\u0160 Ko\u0161ice Ko\u0161ice, Trieda SNP 1, 040 66. Szlov\u00e1kia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1\u0161","family":"Koky","sequence":"additional","affiliation":[{"name":"II. Intern\u00e1 Klinika UNLP a LF UPJ\u0160 Ko\u0161ice Ko\u0161ice Szlov\u00e1kia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivica","family":"Laz\u00farov\u00e1","sequence":"additional","affiliation":[{"name":"I. Intern\u00e1 Klinika UNLP a LF UPJ\u0160 Ko\u0161ice Ko\u0161ice, Trieda SNP 1, 040 66. Szlov\u00e1kia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"R1","doi-asserted-by":"crossref","unstructured":"Cuthbertson D, Smith K, Babraj J, et al. Anabolic signaling deficits\n                    underlie amino acid resistance of wasting, aging muscle. FASEB J. 2005; 19:\n                    1-22. httppps:\/\/doi.org\/10.1096\/fj.04-2640fje","DOI":"10.1096\/fj.04-2640fje"},{"key":"R2","doi-asserted-by":"crossref","unstructured":"Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised\n                    European consensus on definition and diagnosis. Age Ageing 2019; 48: 16-31.\n                        httppps:\/\/doi.org\/10.1093\/ageing\/afy169","DOI":"10.1093\/ageing\/afz046"},{"key":"R3","doi-asserted-by":"crossref","unstructured":"Simon A, Kubik AZs, Boros E, et al. Development and validation of a\n                    questionnaire assessing physiotherapists\u2019 knowledge, attitudes, and practices\n                    regarding falls among older adults. [Gy\u00f3gytorn\u00e1sz-fizioterapeut\u00e1k id\u0151skori\n                    eles\u00e9ssel kapcsolatos tud\u00e1s\u00e1nak, attit\u0171dj\u00e9nek \u00e9s gyakorlat\u00e1nak felm\u00e9r\u00e9s\u00e9re\n                    szolg\u00e1l\u00f3 k\u00e9rd\u0151\u00edv kifejleszt\u00e9se \u00e9s valid\u00e1l\u00e1sa.] Orv Hetil. 2026; 167: 811-823.\n                    [Hungarian] httppps:\/\/doi.org\/10.1556\/650.2026.33545","DOI":"10.1556\/650.2026.33545"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"Moln\u00e1r A, J\u00f3n\u00e1sn\u00e9 Sztruh\u00e1r I, Csontos \u00c1A, et al. Special nutrition\n                    intervention is required for muscle protective efficacy of physical exercise in\n                    elderly people at highest risk of sarcopenia. Physiol Int. 2016; 103: 368-376.\n                        httppps:\/\/doi.org\/10.1556\/2060.103.2016.3.12","DOI":"10.1556\/2060.103.2016.3.12"},{"key":"R5","doi-asserted-by":"crossref","unstructured":"Kov\u00e1cs \u00c9, J\u00f3n\u00e1sn\u00e9 Sztruh\u00e1r I, Asiama E, et al. Prevalence and\n                    associated factors of sarcopenia among older adults living in institutions\n                    providing long-term care. [A sarcopenia prevalenci\u00e1ja, valamint az eg\u00e9szs\u00e9g- \u00e9s\n                    \u00e9letm\u00f3dbeli t\u00e9nyez\u0151kkel val\u00f3 kapcsolata a tart\u00f3s ell\u00e1t\u00e1st ny\u00fajt\u00f3 int\u00e9zm\u00e9nyekben\n                    \u00e9l\u0151 id\u0151sek k\u00f6r\u00e9ben.] Orv Hetil. 2016; 157: 1847-1853. [Hungarian]\n                        httppps:\/\/doi.org\/10.1556\/650.2016.30600","DOI":"10.1556\/650.2016.30600"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"de Luis Rom\u00e1n D, G\u00f3mez JC, Garc\u00eda-Almeida JM, et al. Diabetic\n                    sarcopenia. A proposed muscle screening protocol in people with diabetes. Expert\n                    document. Rev Endocr Metab Disord. 2024; 25: 651-661.\n                        httppps:\/\/doi.org\/10.1007\/s11154-023-09871-9","DOI":"10.1007\/s11154-023-09871-9"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"Prado CM, Landi F, Chew ST. Advances in muscle health and nutrition:\n                    A toolkit for healthcare professionals. Clin Nutr. 2022; 41: 2244-2263.\n                        httppps:\/\/doi.org\/10.1016\/j.clnu.2022.07.041","DOI":"10.1016\/j.clnu.2022.07.041"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"Martone AM, Ciciarello F, Galluzzo V, et al. A simple medical device\n                    development according to normative values of calf circumference across ages:\n                    results from the Italian Longevity Check-up 7+ (Lookup 7+) project. J Cachexia\n                    Sarcopenia Muscle 2024; 15: 36-44.\n                        httppps:\/\/doi.org\/10.1002\/jcsm.13286","DOI":"10.1002\/jcsm.13286"},{"key":"R9","unstructured":"European Association for the Study of the Liver (EASL); European\n                    Association for the Study of Diabetes (EASD); European Association for the Study\n                    of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines on the management\n                    of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol.\n                    2024; 81: 492-542."},{"key":"R10","doi-asserted-by":"crossref","unstructured":"Rigor J, Vasconcelos R, Lopes R, et al. Associations between muscle\n                    mass, strength, and performance and non-alcoholic fatty liver disease. Minerva\n                    Gastroenterol (Torino) 2023; 69: 374-381.\n                        httppps:\/\/doi.org\/10.23736\/S2724-5985.22.03097-2","DOI":"10.23736\/S2724-5985.22.03097-2"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Feng L, Gao Q, Hu K, et al. Prevalence and risk factors of\n                    sarcopenia in patients with diabetes: a meta-analysis. J Clin Endocrinol Metab.\n                    2022; 107: 1470-1483.\n                    httppps:\/\/doi.org\/10.1210\/clinem\/dgab884","DOI":"10.1210\/clinem\/dgab884"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Qiao YS, Chai YH, Gong HJ, et al. The association between diabetes\n                    mellitus and risk of sarcopenia: Accumulated evidences from observational\n                    studies. Front Endocrinol (Lausanne) 2021; 12: 782391.\n                        httppps:\/\/doi.org\/10.3389\/fendo.2021.782391","DOI":"10.3389\/fendo.2021.782391"},{"key":"R13","doi-asserted-by":"crossref","unstructured":"Prado CM, Orsso CE, Pereira SL, et al. Effects of \u03b2-hydroxy\n                    \u03b2-methylbutyrate (HMB) supplementation on muscle mass, function, and other\n                    outcomes in patients with cancer: a systematic review. J Cachexia Sarcopenia\n                    Muscle 2022; 13: 1623-1641.\n                    httppps:\/\/doi.org\/10.1002\/jcsm.12952","DOI":"10.1002\/jcsm.12952"},{"key":"R14","doi-asserted-by":"crossref","unstructured":"Vukovich MD, Stubbs NB, Bohlken RM. Body composition in 70-year-old\n                    adults responds to dietary beta-hydroxy-beta-methylbutyrate similarly to that of\n                    young adults. J Nutr. 2001; 131: 2049-2052.\n                        httppps:\/\/doi.org\/10.1093\/jn\/131.7.2049","DOI":"10.1093\/jn\/131.7.2049"},{"key":"R15","doi-asserted-by":"crossref","unstructured":"Dutt V, Gupta S, Dabur R, et al. Skeletal muscle atrophy: potential\n                    therapeutic agents and their mechanisms of action. Pharmacol Res. 2015; 99:\n                    86-100. httppps:\/\/doi.org\/10.1016\/j.phrs.2015.05.010","DOI":"10.1016\/j.phrs.2015.05.010"},{"key":"R16","doi-asserted-by":"crossref","unstructured":"Wilkinson DJ, Hossain T, Hill DS, et al. Effects of leucine and its\n                    metabolite \u03b2-hydroxy-\u03b2-methylbutyrate on human skeletal muscle protein\n                    metabolism. J Physiol. 2013; 591: 2911-2923.\n                        httppps:\/\/doi.org\/10.1113\/jphysiol.2013.253203","DOI":"10.1113\/jphysiol.2013.253203"},{"key":"R17","doi-asserted-by":"crossref","unstructured":"Cruz-Jentoft AJ. Beta-hydroxy-beta-methyl butyrate (HMB): from\n                    experimental data to clinical evidence in sarcopenia. Curr Protein Pept Sci.\n                    2018; 19: 668-672.\n                        httppps:\/\/doi.org\/10.2174\/1389203718666170529105026","DOI":"10.2174\/1389203718666170529105026"},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Kaczka P, Michalczyk MM, Jastrz\u0105b R, et al. Mechanism of action and\n                    the effect of beta-hydroxy-beta-methylbutyrate (HMB) supplementation on\n                    different types of physical performance - a systematic review. J Hum Kinet.\n                    2019; 68: 211-222.\n                    httppps:\/\/doi.org\/10.2478\/hukin-2019-0070","DOI":"10.2478\/hukin-2019-0070"},{"key":"R19","doi-asserted-by":"crossref","unstructured":"Gerlinger-Romero F, Guimar\u00e3es-Ferreira L, Giannocco G, et al.\n                    Chronic supplementation of beta-hydroxy-beta methylbutyrate (HM\u03b2) increases the\n                    activity of the GH\/IGF-I axis and induces hyperinsulinemia in rats. Growth Horm\n                    IGF Res. 2011; 21: 57-62.\n                        httppps:\/\/doi.org\/10.1016\/j.ghir.2010.12.006","DOI":"10.1016\/j.ghir.2010.12.006"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"Stout JR, Smith-Ryan AE, Fukuda DH, et al. Effect of calcium\n                    \u03b2-hydroxy-\u03b2-methylbutyrate (CaHMB) with and without resistance training in men\n                    and women 65+yrs: a randomized, double-blind pilot trial. Exp Gerontol. 2013;\n                    48: 1303-1310.\n                    httppps:\/\/doi.org\/10.1016\/j.exger.2013.08.007","DOI":"10.1016\/j.exger.2013.08.007"},{"key":"R21","doi-asserted-by":"crossref","unstructured":"Bear DE, Langan A, Dimidi E, et al. \u03b2-Hydroxy-\u03b2-methylbutyrate and\n                    its impact on skeletal muscle mass and physical function in clinical practice: a\n                    systematic review and meta-analysis. Am J Clin Nutr. 2019; 109: 1119-1132.\n                        httppps:\/\/doi.org\/10.1093\/ajcn\/nqy373","DOI":"10.1093\/ajcn\/nqy373"},{"key":"R22","doi-asserted-by":"crossref","unstructured":"Lin Z, Zhao Y, Chen Q. Effects of oral administration of \u03b2-hydroxy\n                    \u03b2-methylbutyrate on lean body mass in older adults: a systematic review and\n                    meta-analysis. Eur Geriatr Med. 2021; 12: 239-251.\n                        httppps:\/\/doi.org\/10.1007\/s41999-020-00409-9","DOI":"10.1007\/s41999-020-00409-9"},{"key":"R23","doi-asserted-by":"crossref","unstructured":"Courel-Ib\u00e1\u00f1ez J, Vetrovsky T, Dadova K, et al. Health benefits of\n                    \u03b2-hydroxy-\u03b2-methylbutyrate (HMB) supplementation in addition to physical\n                    exercise in older adults: a systematic review with meta-analysis. Nutrients\n                    2019; 11: 2082. httppps:\/\/doi.org\/10.3390\/nu11092082","DOI":"10.3390\/nu11092082"},{"key":"R24","doi-asserted-by":"crossref","unstructured":"L\u00f3pez-G\u00f3mez JJ, Gonz\u00e1lez-Guti\u00e9rrez J, P\u00e9rez-L\u00f3pez P, et al. Effect\n                    of calcium hydroxy-methyl-butyrate-enriched diabetes-specific oral nutritional\n                    supplementation on patients with heterogeneous diabetes mellitus population with\n                    disease related malnutrition assessed with AI-assisted ultrasound imaging.\n                    Nutrients 2025; 17: 3208.\n                    httppps:\/\/doi.org\/10.3390\/nu17203208","DOI":"10.3390\/nu17203208"},{"key":"R25","doi-asserted-by":"crossref","unstructured":"Sanz-Par\u00eds A, Mat\u00eda-Mart\u00edn P, Mart\u00edn-Palmero \u00c1, et al.\n                    Diabetes-specific formulas high in monounsaturated fatty acids and metabolic\n                    outcomes in patients with diabetes or hyperglycaemia. A systematic review and\n                    meta-analysis. Clin Nutr. 2020; 39: 3273-3282.\n                        httppps:\/\/doi.org\/10.1016\/j.clnu.2020.02.036","DOI":"10.1016\/j.clnu.2020.02.036"},{"key":"R26","doi-asserted-by":"crossref","unstructured":"Nunan D, Howatson G, van Someren KA. Exercise-induced muscle damage\n                    is not attenuated by beta-hydroxy-beta-methylbutyrate and alpha-ketoisocaproic\n                    acid supplementation. J Strength Cond Res. 2010; 24: 531-537.\n                        httppps:\/\/doi.org\/10.1519\/JSC.0b013e3181c4d370","DOI":"10.1519\/JSC.0b013e3181c4d370"},{"key":"R27","doi-asserted-by":"crossref","unstructured":"Holland BM, Roberts BM, Krieger JW, et al. Does HMB enhance body\n                    composition in athletes? A systematic review and meta-analysis. J Strength Cond\n                    Res. 2022; 36: 585-592.\n                        httppps:\/\/doi.org\/10.1519\/JSC.0000000000003461","DOI":"10.1519\/JSC.0000000000003461"},{"key":"R28","doi-asserted-by":"crossref","unstructured":"Morton RW, Murphy KT, McKellar SR, et al. A systematic review,\n                    meta-analysis and meta-regression of the effect of protein supplementation on\n                    resistance training-induced gains in muscle mass and strength in healthy adults.\n                    Br J Sports Med. 2018; 52: 376-384. Erratum: Br J Sports Med. 2020; 54: e7.\n                        httppps:\/\/doi.org\/10.1136\/bjsports-2017-097608","DOI":"10.1136\/bjsports-2017-097608corr1"},{"key":"R29","doi-asserted-by":"crossref","unstructured":"Deutz NE, Pereira SL, Hays NP, et al. Effect of\n                    \u03b2-hydroxy-\u03b2-methylbutyrate (HMB) on lean body mass during 10 days of bed rest in\n                    older adults. Clin Nutr. 2013; 32: 704-712.\n                        httppps:\/\/doi.org\/10.1016\/j.clnu.2013.02.011","DOI":"10.1016\/j.clnu.2013.02.011"},{"key":"R30","doi-asserted-by":"crossref","unstructured":"Hole\u010dek M. Beta-hydroxy-beta-methylbutyrate supplementation and\n                    skeletal muscle in healthy and muscle-wasting conditions. J Cachexia Sarcopenia\n                    Muscle 2017; 8: 529-541.\n                    httppps:\/\/doi.org\/10.1002\/jcsm.12208","DOI":"10.1002\/jcsm.12208"},{"key":"R31","doi-asserted-by":"crossref","unstructured":"Atherton PJ, Etheridge T, Watt PW, et al. Muscle full effect after\n                    oral protein: time-dependent concordance and discordance between human muscle\n                    protein synthesis and mTORC1 signaling. Am J Clin Nutr. 2010; 92: 1080-1088.\n                        httppps:\/\/doi.org\/10.3945\/ajcn.2010.29819","DOI":"10.3945\/ajcn.2010.29819"},{"key":"R32","doi-asserted-by":"crossref","unstructured":"Greenhaff PL, Karagounis LG, Peirce N, et al. Disassociation between\n                    the effects of amino acids and insulin on signaling, ubiquitin ligases, and\n                    protein turnover in human muscle. Am J Physiol Endocrinol Metab. 2008; 295:\n                    E595-E604.\n                    httppps:\/\/doi.org\/10.1152\/ajpendo.90411.2008","DOI":"10.1152\/ajpendo.90411.2008"},{"key":"R33","doi-asserted-by":"crossref","unstructured":"Osuka Y, Kojima N, Sasai H, et al. Effects of exercise and\/or\n                    \u03b2-hydroxy-\u03b2-methylbutyrate supplementation on muscle mass, muscle strength, and\n                    physical performance in older women with low muscle mass: a randomized,\n                    double-blind, placebo-controlled trial. Am J Clin Nutr. 2021; 114: 1371-1385.\n                        httppps:\/\/doi.org\/10.1093\/ajcn\/nqab176","DOI":"10.1093\/ajcn\/nqab176"},{"key":"R34","doi-asserted-by":"crossref","unstructured":"Leroux M, Lemery T, Boulet, et al. Effects of the amino acid\n                    derivatives, \u03b2-hydroxy-\u03b2-methylbutyrate, taurine, and N-methyltyramine, on\n                    triacylglycerol breakdown in fat cells. J Physiol Biochem. 2019; 75: 263-273.\n                        httppps:\/\/doi.org\/10.1007\/s13105-019-00677-5","DOI":"10.1007\/s13105-019-00677-5"},{"key":"R35","doi-asserted-by":"crossref","unstructured":"Bruckbauer A, Zemel MB, Thorpe T, et al. Synergistic effects of\n                    leucine and resveratrol on insulin sensitivity and fat metabolism in adipocytes\n                    and mice. Nutr Metab (Lond) 2012; 9: 77.\n                        httppps:\/\/doi.org\/10.1186\/1743-7075-9-77","DOI":"10.1186\/1743-7075-9-77"},{"key":"R36","doi-asserted-by":"crossref","unstructured":"Lynch CJ, Adams SH. Branched-chain amino acids in metabolic\n                    signalling and insulin resistance. Nat Rev Endocrinol. 2014; 10: 723-736.\n                        httppps:\/\/doi.org\/10.1038\/nrendo.2014.171","DOI":"10.1038\/nrendo.2014.171"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/167\/38\/article-p1507.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/167\/38\/article-p1507.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/167\/38\/article-p1507.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T05:55:21Z","timestamp":1789883721000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/167\/38\/article-p1507.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,20]]},"references-count":36,"journal-issue":{"issue":"38"},"URL":"https:\/\/doi.org\/10.1556\/650.2026.33671","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,20]]}}}